Fleet Renewal Momentum And Index Inclusion Will Drive Long-Term Market Prominence

Analysts have sharply raised their price target for Randoncorp, with recent increases of as much as $45 per share. They cite strong Phase 2 clinical data and growing confidence in the company’s expanding therapeutic pipeline.

Randoncorp's analyst price target has been revised downward from $9.83 to $9.23 per share, as analysts cite lower projected revenue growth and profit margins in their updated fair value assessment. Analyst Commentary Following the revision in price target for Randoncorp, recent commentary from the analyst community highlights both optimism and lingering caution around the company's outlook.

Randoncorp's analyst price target has been revised downward from $10.74 to $9.83 per share. Analysts cite a more cautious outlook on profit margins, despite modestly improved revenue growth expectations.

The consensus analyst price target for Randoncorp has been reduced primarily due to a lower forward P/E multiple, while revenue growth forecasts remain stable, resulting in a new fair value estimate of R$10.74. What's in the News Randoncorp added to the Brazil IBRX Index.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased profit margin from 5.3% to 4.4% and increased future PE multiple from 9.6x to 11.6x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased profit margin from 4.1% to 5.3% and decreased future PE multiple from 12.6x to 9.6x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased revenue growth from 12.8% to 15.1%, increased profit margin from 3.6% to 4.1% and decreased shares outstanding growth rate from 0.0% to 0.0%.